Core Viewpoint - ZIVO Bioscience, Inc. has decided to deregister its securities with the SEC and cease public reporting, believing this is in the best interests of shareholders at this stage of development [2][3]. Financial Considerations - The costs associated with maintaining a public listing, including SEC compliance, legal, financial reporting, and investor relations, are significant and consume a disproportionate share of resources for a company of ZIVO's size [3]. - Ongoing capital raises to fund public reporting expenses have led to shareholder dilution, reducing the ownership percentage of existing shareholders [4]. Revenue Potential - ZIVO anticipates meaningful revenue from its AgTech product line in the coming months due to established distribution relationships and advancing commercial activity [4]. - As a non-reporting company, ZIVO expects to retain and accumulate revenue and cash for the direct benefit of the company, potentially resulting in positive cash flow for the first time in its history [5]. Business Updates - The Animal Health division is progressing, with major global companies conducting due diligence on ZIVO's non-antibiotic immune-modulating technology, with formal partnership discussions anticipated [6]. - The University of Georgia has received funding to use ZIVO's product in studies addressing Avian Influenza, a significant issue for the poultry industry [7]. - In the AgTech and Human Nutrition segment, ZIVO LIFE™ microalgae ingredient has generated global commercial interest, and production capacity is being increased in anticipation of growing demand [8]. Commitment to Shareholders - The Board of Directors has eliminated board compensation and any investments by board members are made at full market price, demonstrating alignment with shareholder interests [9]. - The decision to cease public reporting is framed as a commitment to a better structure for building value, with shareholder interests at the center of decision-making [10].

Company Overview - Cogent Biosciences is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined diseases, leveraging precision medicine to address unmet medical needs in oncology and rare disease markets [5] - The company has a lead product candidate, CGT9486, aimed at treating systemic mastocytosis and advanced gastrointestinal stromal tumors, and operates through a biotechnology R&D model [8] Financial Performance - As of February 17, 2026, Cogent Biosciences had a market capitalization of $5.6 billion and a net income of -$328.94 million (TTM) [4] - The company's stock price was $34.40, reflecting a 372% increase over the past year, significantly outperforming the S&P 500's 16% gain during the same period [7] Recent Developments - Boone Capital Management sold its entire stake of 945,042 shares in Cogent Biosciences, liquidating a position valued at $13.57 million [1][2] - Despite the liquidation, Cogent is reported to be in a strong position with approximately $900 million in cash and a clear path toward potential commercialization, including multiple NDA filings [9] Market Position and Strategy - Cogent's strategy includes advancing innovative kinase inhibitors and forming strategic collaborations, such as its partnership with Plexxikon Inc. for bezuclastinib [5][8] - The company targets patients with rare genetic mutations, particularly those affected by KIT-driven cancers and systemic mastocytosis, serving the global biopharmaceutical and healthcare markets [8]

Financial Data and Key Metrics Changes - In Q4 2025, cell engineering revenue was $26 million, down 26% compared to Q4 2024, with a total of 109 revenue-generating programs, a 4% decrease year-over-year [15][16] - For the full year 2025, cell engineering revenue was $133 million, down from $174 million in 2024, primarily due to customer program rationalization [15][16] - Total Adjusted EBITDA in Q4 2025 was -$36 million, an improvement from -$57 million in Q4 2024, while for the full year, it was -$167 million, up from -$293 million in 2024 [20][21] - Cash burn in Q4 2025 was $47 million, down from $55 million in Q4 2024, and for the full year, it was $171 million, a 55% decrease from $383 million in 2024 [22][24] Business Line Data and Key Metrics Changes - The biosecurity business generated $7 million in revenue in Q4 2025 and $37 million for the full year, with an operating loss improvement of 60% in Q4 2025 compared to 2024 [17][20] - Cell engineering R&D expenses decreased 44% in Q4 2025 to $28 million, and for the full year, it decreased 42% to $159 million [18][19] Market Data and Key Metrics Changes - The company is focusing on the autonomous lab market, which is expected to transform biotechnology and is seen as a high-value area for investment [3][4] - The federal government and pharmaceutical companies are significant pools of research spending, with the NIH spending $40 billion annually on lab work [31][62] Company Strategy and Development Direction - The company plans to divest its biosecurity business to focus investments on autonomous labs, aiming to demonstrate capabilities through a large autonomous lab in Boston [4][11] - The strategy includes booking sales of autonomous labs to national labs and biopharma, with a notable $47 million deal with Pacific Northwest National Laboratory [6][31] - The company aims to improve cost efficiency while investing in AI robotics and software for autonomous labs, with a cash burn guidance of $125 million to $150 million for 2026 [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of autonomous labs to replace traditional manual laboratories, emphasizing the importance of long-term orientation over short-term revenue targets [28][29] - The company highlighted the need for flexibility in lab operations and the potential for AI to enhance research productivity [59][60] Other Important Information - The company has made significant strides in reducing cash burn and controlling spending, setting a solid foundation for future investments [13][14] - The autonomous lab is positioned as a solution to save overhead costs and increase research productivity for biopharma and national labs [59][60] Q&A Session Summary Question: What is the outlook for revenue guidance in 2026? - The company will not provide revenue guidance for 2026, focusing instead on cash burn as a better reflection of ongoing services and investments in autonomous labs [24][25] Question: How does the company plan to commercialize autonomous labs? - The company plans to build autonomous labs for customers and offer cloud lab services, allowing scientists to outsource small lab work directly [61][62]

Financial Data and Key Metrics Changes - In Q4 2025, cell engineering revenue was $26 million, down 26% from Q4 2024, with a total of 109 revenue-generating programs, a 4% decrease year-over-year [16] - For the full year 2025, cell engineering revenue was $133 million, down from $174 million in 2024, primarily due to customer program rationalization [16] - Total Adjusted EBITDA in Q4 2025 was -$36 million, an improvement from -$57 million in Q4 2024, while for the full year, it was -$167 million, up from -$293 million in 2024 [21][22] - Cash burn in Q4 2025 was $47 million, down from $55 million in Q4 2024, and for the full year, it was $171 million, a 55% decrease from $383 million in 2024 [23] Business Line Data and Key Metrics Changes - The biosecurity business generated $7 million in revenue in Q4 2025 and $37 million for the full year, with an operating loss improvement of 60% in Q4 compared to 2024 [18][21] - Cell engineering R&D expenses decreased 44% in Q4 2025 to $28 million, and for the full year, it decreased 42% to $159 million [19][20] Market Data and Key Metrics Changes - The company plans to focus on the autonomous lab market, which is expected to transform biotechnology and attract significant investment from both federal and private sectors [3][32] - The federal government, including the NIH, spends approximately $40 billion annually on lab work, indicating a substantial market opportunity for autonomous labs [32] Company Strategy and Development Direction - The company intends to divest its biosecurity business to concentrate investments on autonomous labs, aiming to demonstrate capabilities through a large autonomous lab in Boston [4][6] - The strategy includes systematic decommissioning of traditional lab setups to transition to a fully autonomous lab model, showcasing its potential to major pharmaceutical companies [5][30] - The company aims to book sales of autonomous labs to national labs, biopharma, and research universities, with a notable $47 million deal already secured [6][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of autonomous labs to replace traditional manual laboratories, emphasizing the importance of long-term investment over short-term revenue targets [27][30] - The outlook for 2026 includes a focus on cost efficiency while investing in AI and robotics to enhance autonomous lab capabilities, with expected cash burn guidance set between $125 million and $150 million [24][25] Other Important Information - The company has made significant strides in reducing cash burn and improving cost efficiency, setting a solid foundation for future investments [26] - The autonomous lab initiative is positioned as a key technological foundation for the company over the next decade, with plans to expand lab capacity significantly [35][36] Q&A Session Summary Question: What is the company's long-term growth outlook? - The company is focusing on investing in autonomous labs, with a strategic shift away from short-term revenue targets to long-term capabilities and market leadership in this emerging field [27][30] Question: How does the company plan to commercialize autonomous labs? - The company will build autonomous labs for customers and offer cloud lab services, allowing scientists to engage with the technology before committing to larger investments [62][66]

Financial Data and Key Metrics Changes - In Q4 2025, cell engineering revenue was $26 million, down 26% from Q4 2024, with a total of 109 revenue-generating programs, a 4% decrease year-over-year [15][16] - For the full year 2025, cell engineering revenue was $133 million, down from $174 million in 2024, with a significant reduction in cash burn from $383 million in 2024 to $171 million in 2025, a 55% decrease [13][22] - Total Adjusted EBITDA for Q4 2025 was -$36 million, an improvement from -$57 million in Q4 2024, while for the full year, it was -$167 million, down from -$293 million in 2024 [20][21] Business Line Data and Key Metrics Changes - The biosecurity business generated $7 million in revenue in Q4 2025 and $37 million for the full year, with an operating loss improvement of 60% in Q4 2025 compared to 2024 [16][20] - Cell engineering R&D expenses decreased by 44% in Q4 2025 to $28 million, and for the full year, it decreased by 42% to $159 million, attributed to restructuring efforts [18][19] Market Data and Key Metrics Changes - The company is focusing on the autonomous lab market, which is expected to transform biotechnology, with significant interest from federal government spending and biopharma sectors [31][63] - The company plans to commercialize autonomous labs through direct sales and cloud lab services, targeting a market that includes $40 billion to $60 billion in pharma research spending [62][63] Company Strategy and Development Direction - The company intends to divest its biosecurity business to focus investments on autonomous labs, aiming to demonstrate capabilities through a large autonomous lab in Boston [4][11] - The strategy for 2026 includes cost efficiency while investing in AI robotics and software to enhance autonomous labs, with a cash burn guidance of $125 million to $150 million [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of autonomous labs to replace traditional manual laboratories, emphasizing the importance of long-term investment over short-term revenue targets [27][29] - The company highlighted the successful collaboration with OpenAI, showcasing advancements in AI-driven scientific experimentation [30] Other Important Information - The company has made significant strides in reducing cash burn and improving operational efficiency, setting a solid foundation for future investments in autonomous labs [14][22] - The company is actively engaging with top pharma customers and government entities, indicating strong market interest in its solutions [67] Q&A Session Summary Question: What is the outlook for revenue guidance in 2026? - The company will not provide revenue guidance for 2026, focusing instead on cash burn as a better reflection of ongoing services and investments in autonomous labs [23] Question: How does the company plan to commercialize autonomous labs? - The company plans to build autonomous labs for customers and offer cloud lab services, allowing scientists to engage with the technology before committing to larger investments [62][66]

Core Insights - Ginkgo Bioworks' Co-Founder and CEO Jason Kelly will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 [1] Company Overview - Ginkgo Bioworks specializes in engineering biology, providing customizable R&D solutions including protein engineering, nucleic acid design, and cell-free systems to accelerate innovation in therapeutics, diagnostics, and manufacturing [2] - The company offers modular laboratory automation through Ginkgo Automation, allowing scientists to focus on planning and analyzing experiments rather than manual pipetting [2] - Ginkgo Datapoints utilizes in-house automation to generate large lab datasets that support AI model development [2] - Ginkgo Biosecurity is focused on creating next-generation infrastructure and technologies for predicting, detecting, and responding to biological threats [2]

Core Insights - Ginkgo Bioworks has partnered with Deep Origin on a 4.5-year project funded by ARPA-H to develop a computational platform for drug safety [1][4] - The collaboration, named PREDICTS, aims to enhance pharmacological research through digital integration and clinical trial simulation [1][4] Company Overview - Ginkgo Bioworks specializes in engineering biology and offers customizable R&D solutions, including protein engineering and nucleic acid design [6] - The company utilizes its 'Datapoints' platform to generate large, structured datasets for AI model training, focusing on drug safety and efficacy [2][4] Project Details - The PREDICTS project will leverage Ginkgo's high-throughput capabilities to create detailed models of cellular responses to drug treatments [3][4] - The initiative will include various readouts such as cell type-specific toxicity endpoints and DRUG-seq transcriptomics [2] Strategic Importance - This partnership highlights Ginkgo's commitment to interdisciplinary collaboration and its expertise in generating large datasets for drug development [4] - The collaboration is expected to push the boundaries of multi-omics data generation, transforming drug discovery processes [4]

Core Insights - The presentation aims to provide an overview of the company's advancements in proteomics and the associated challenges in understanding the complexity of the proteome [1] - The focus is on the Proteus program, which represents the majority of the company's R&D investment, highlighting its significance in enhancing performance [1] Group 1: Technology and R&D - The company is investing heavily in the Proteus program, which is central to its current R&D efforts [1] - There are also modest investments in long-term technology development, indicating a balanced approach to immediate and future innovations [1] Group 2: Future Developments - Upcoming discussions will include plans to expand to 20 amino acids, with details on the timeline for achieving this goal [2]

Company Overview - Volition is a multinational company with laboratories in Belgium and San Diego, USA, focused on stabilizing and improving health outcomes for millions globally [4]. Technology Insights - The presentation highlights the Nu.Q technology, which is aimed at accelerating epigenetic drug development [3][4]. - Nucleosomes, the fundamental structural units of chromatin, are essential for compacting DNA into chromosomes, allowing the genome to fit into the cell nucleus [5].

Core Insights - Hypha Labs, Inc. has officially launched Phase II of its strategic partnership with Tryptomics, focusing on the development of functional mushroom technologies [1] - The collaboration combines Hypha's patented Mushroom Accelerator™ platform with Tryptomics' On-Site™ Science Services and contract R&D Metabolomics Pipeline [1] - This partnership aims to create proprietary varieties of bioreactor-optimized species and enhance quality assurance testing at Hypha Labs, thereby accelerating R&D cycles [1] Company Developments - The partnership with Tryptomics is expected to advance the future of at-home, pharmaceutical-grade mushroom wellness [1] - Hypha Labs is positioned to lead in the biotechnology sector by leveraging innovative technologies in functional mushrooms [1]